Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Str…
Fosun Pharma reported a 21.96% YoY increase in net profit attributable to shareholders after deducting non-recurring gains and losses in Q1 2026. The company achieved significant milestones in its innovation transformation, including the acceptance of NDAs for four innovative drugs by the NMPA or U.S. FDA.
Fosun Pharma announced its Q1 2026 results, with total revenue reaching RMB 10,073 million, a 6.93% YoY increase. Net profit attributable to shareholders after deducting extraordinary gain or loss was RMB 501 million, up 21.96% YoY. The company invested RMB 897 million in R&D, a 1.59% YoY increase. Fosun Pharma's innovation transformation is driven by its strategy of 'Innovation Driven, Deep Globalization, and AI Embracement'. The company has made significant progress in its antibody/ADC technology platform, with denosumab injection (HLX14) securing approval in Canada and the NDA for bevacizumab injection (HLX04) being accepted in the U.S. In the small molecule innovative drug platform, the NDA for foritinib succinate capsules (SAF-189) was accepted by the NMPA for the treatment of ALK-positive NSCLC.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.